Neutral Dr Reddy's Laboratories, target Rs 3400: UBS
The R&D spend is likely to increase led by proprietary products. In-license deals are likely to aid India business
By 
| Updated:
| Updated: UBS maintains a neutral rating on Dr Reddy's Laboratories with a 12-month target price of Rs 3400. The global investment bank expects pricing pressure in US to normalize next year; and new launches in H2.
The R&D spend is likely to increase led by proprietary products. In-license deals are likely to aid India business. UBS further added that growth in Russia could pick up with potential tender wins in Rituximab.
The R&D spend is likely to increase led by proprietary products. In-license deals are likely to aid India business. UBS further added that growth in Russia could pick up with potential tender wins in Rituximab.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
Dr Reddy's Laboratories Q4 Results: Cons PAT falls 86% YoY to Rs 221 crore, revenue dips 12%; Rs 8 per share dividend announced2026-05-12T11:28:57Z- Buy, Sell or Hold: DAM Capital initiates coverage on Orkla India; Citi maintains sell on Dr Reddy's Laboratories2026-04-15T04:33:57Z
- Dr Reddy's Laboratories Q3 Results: Profit falls 14% YoY to Rs 1,210 crore, revenue up 4%2026-01-21T11:42:20Z
ADVERTISEMENT
